Silicon Valley investors have been conditioned by two decades of software: launch quickly, capture users faster, and hit the magic $1 million ARR mark within about three years,1
Buoyed by growth opportunities and the strengthening economy, 2024 turned out to be an interesting year for the United Kingdom’s (UK) healthcare advertising industry.
The UK stands at the cusp of a new era of medical breakthroughs, fuelled by the increased use of data and the recent plans to open NHS data reserves to improve the development and creation
Boehringer’s Medicine Excellence initiative harnesses technology with the aim to build a ‘One Medicine Platform’, unifying development processes and data in a centralised platform.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.